Literature DB >> 22674709

Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.

E Thornton1, S A Howard, J Jagannathan, K M Krajewski, A B Shinagare, K O'Regan, J M Cleary, N H Ramaiya.   

Abstract

Molecular targeted therapies are becoming ubiquitous in cancer treatment. These drugs may cause gastrointestinal toxicities including perforation, pneumatosis, enteritis, colitis and fistula formation. Knowledge of these complications and their management enables early radiological identification and appropriate intervention, reducing patient morbidity and mortality.

Entities:  

Mesh：

Year:  2012        PMID： 22674709      PMCID： PMC3474016          DOI： 10.1259/bjr/19815818

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  13 in total

1.  Managing bevacizumab-related toxicities in patients with colorectal cancer.

Authors:  M Wasif Saif
Journal:  J Support Oncol       Date:  2009 Nov-Dec

2.  Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.

Authors:  Timothy R Asmis; Ki Y Chung; Jerrold B Teitcher; David P Kelsen; Manish A Shah
Journal:  Invest New Drugs       Date:  2007-10-26       Impact factor: 3.850

3.  Everolimus- and temsirolimus-associated enteritis: report of three cases.

Authors:  Kavitha Parithivel; Nikhil Ramaiya; Jyothi Priya Jagannathan; Kevin O'Regan; Katherine Krajewski; David Fisher; Toni K Choueiri; Eric Jacobsen
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Authors:  D L Richardson; F J Backes; J D Hurt; L G Seamon; L J Copeland; J M Fowler; D E Cohn; D M O'Malley
Journal:  Gynecol Oncol       Date:  2010-04-10       Impact factor: 5.482

6.  Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.

Authors:  Wells A Messersmith; Antonio Jimeno; Heather Jacene; Ming Zhao; Piotr Kulesza; Daniel A Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine Iacobuzio-Donahue; Ross C Donehower; Michael Carducci; Michelle A Rudek; Manuel Hidalgo
Journal:  Clin Colorectal Cancer       Date:  2010-12       Impact factor: 4.481

7.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

8.  Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.

Authors:  Henry Chow; Adam Jung; Jason Talbott; Amy M Lin; Adil I Daud; Fergus V Coakley
Journal:  J Comput Assist Tomogr       Date:  2011 Jan-Feb       Impact factor: 1.826

Review 9.  Management of bevacizumab-associated bowel perforation: a case series and review of the literature.

Authors:  B D Badgwell; E R Camp; B Feig; R A Wolff; C Eng; L M Ellis; J N Cormier
Journal:  Ann Oncol       Date:  2007-11-16       Impact factor: 32.976

Review 10.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.

Authors:  Sanjaykumar Hapani; David Chu; Shenhong Wu
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316
View more
  8 in total

Review 1.  CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.

Authors:  Maxime Barat; Sarah Guegan-Bart; Anne-Ségolène Cottereau; Enora Guillo; Christine Hoeffel; Maximilien Barret; Sébastien Gaujoux; Anthony Dohan; Philippe Soyer
Journal:  Abdom Radiol (NY)       Date:  2020-11-02

Review 2.  Update on the role of imaging in management of metastatic colorectal cancer.

Authors:  Sree Harsha Tirumani; Kyung Won Kim; Mizuki Nishino; Stephanie A Howard; Katherine M Krajewski; Jyothi P Jagannathan; James M Cleary; Nikhil H Ramaiya; Atul B Shinagare
Journal:  Radiographics       Date:  2014 Nov-Dec       Impact factor: 5.333

Review 3.  Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.

Authors:  Ailbhe C O'Neill; Jyothi P Jagannathan; Nikhil H Ramaiya
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

4.  Diarrhea Concealing a Duodenal-Cecal Fistula Secondary to Appendiceal Mucinous Neoplasm.

Authors:  Su Aung; Amanda Cheung; Charlene Prather; Jinping Lai
Journal:  ACG Case Rep J       Date:  2017-01-04

5.  Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer.

Authors:  Stuart A Ostby; Michael Olushoga; Charles A Leath; Samuel L Burleson
Journal:  Clin Pract Cases Emerg Med       Date:  2020-03-27

Review 6.  Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review.

Authors:  Gianluca Gazzaniga; Federica Villa; Federica Tosi; Elio Gregory Pizzutilo; Stefano Colla; Stefano D'Onghia; Giusy Di Sanza; Giulia Fornasier; Michele Gringeri; Maria Victoria Lucatelli; Giulia Mosini; Arianna Pani; Salvatore Siena; Francesco Scaglione; Andrea Sartore-Bianchi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

7.  Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.

Authors:  Venessa Tsang; Anthony Gill; Matti Gild; Brett Lurie; Lucy Blumer; Rhonda Siddall; Roderick Clifton-Bligh; Bruce Robinson
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

8.  Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.

Authors:  Ai Maeda; Masao Nakata; Katsuhiko Shimizu; Takuro Yukawa; Shinsuke Saisho; Riki Okita
Journal:  World J Surg Oncol       Date:  2016-06-29       Impact factor: 2.754
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.